 |
 |
.jpg)
In the Journal of human genetics, we celebrate the first chapter we focus onrecent advances in pharmacogenomics: Study of genetic variability in drug response effect.
In the past ten years, considerable progress has been made in the human genome research, analysis of the international scientific research infrastructure technology and human genome information in the two genomes progress. In particular, genome-wide association studies have found thousands of associated with disease susceptibility and drug response of genetic variation. These findings raise the mechanism of pathogenesis and drug reaction related to ourunderstanding of disease. In addition, the genetic background of this knowledgehas been revealed, contribute to the differences in disease susceptibility andindividual drug reaction between.
The next step is to transform the results into clinical practice. A great influence on some have identified genetic variation, and highly accurate prediction of drug response. Therefore, such "pharmacogenomic markers" are candidates todetermine which patients will benefit from a specific drug. This special sectioncontains eight of pharmacogenomics in clinical research and the current status of the implementation of.
Focus of cancer pharmacogenomics is 5 comments. A rough outline of theinfluence of Hertz and Macleod provide genomic changes related to cancer therapy. They stressed the importance of genetic variation is a cancer patient's prognosis, response, toxicity and exposure forecast example. ICAS described inpharmacogenomics of endocrine therapy for breast cancer. His review revealsthe power of genome-wide association studies, find out the key genes influencing drug response, importance and function study is to elucidate the mechanism of drug response. The key scientific problem research in pharmacogenomics of endocrine therapy for breast cancer by Kiyotani et al. Further discussion. , whofocused on the controversial variants found in evaluation of CYP2D6 reaction to the drug tamoxifen effect. In the study, Chi et al found in the importance and difficulty of entailed blood cancer pharmacogenomics research. In addition, black stone, Yagi and pharmaceuticals and Medical Devices Agency Yu Shan, Japan,regulators to examine the usefulness and pharmacogenomics instruction the limitations of clinical trials in Japan approved anticancer drugs.
Two major adverse drug reaction, drug genome study of cutaneous adverse reactions and drug-induced liver injury serious study, summed up the Kaniwa and Saito. This paper reviews the HLA allele is an important contribution to thephenotype.
Klein and Lee to review progress, and challenges, facing the implementation ofHua Falin, a clinical drug genome as everyone knows anticoagulant studies. In addition, Perry and Shuldiner discuss variants of CYP2C19 and pharmacokinetics and pharmacodynamics, the relationship between clinicalresponse and anti clotting drug clopidogrel in relatively new.
